On the stock market since 2019, it operates in the world of health and science. It has 260 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
There is $240.0M in the vault; even if every debt were paid off, $200.0M would remain.
Over the last 12 months, company executives reported 49 buys and 24 sells. Management buying with its own money is usually read as a good sign.
A loss of $81.3M against $0 in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, PSNL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PSNL is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.